纳武利尤单抗致弥漫性血管内凝血1例

Nivolumab caused disseminated intravascular coagulation in 1 case

关键词:  纳武利尤单抗  弥漫性血管内凝血，个案，不良反应

Key words:  nivolumab  Disseminated intravascular coagulation, individual cases, adverse reactions

摘要:

目的 探讨恶性肿瘤治疗中免疫检查点抑制剂引起的免疫相关弥散性血管内凝血的临床特点和药学监护，为类似病例的诊治提供参考。方法 临床药师收集1例纳武利尤单抗致弥散性血管内凝血患者的诊疗资料，通过评价药物与不良事件之间的关联性，分析患者出现弥散性血管内凝血的用药因素，并在用药治疗过程中实施药学监护。结果 患者经糖皮质激素治疗后，凝血功能改善。结论 纳武利尤单抗可能引起弥散性血管内凝血，在临床中较为罕见，一旦出现类似症状，应积极明确诊断，及时采取治疗措施，保障患者用药安全。

Abstract:

Objective To investigate the clinical characteristics and pharmaceutical monitoring of immune-related disseminated intravascular coagulation caused by immune checkpoint inhibitors in the treatment of malignant tumors, and to provide a reference for the diagnosis and treatment of similar cases. Methods The clinical pharmacist collected the diagnosis and treatment data of one patient with disseminated intravascular coagulation caused by nivolumab, evaluated the correlation between drugs and adverse events, analyzed the medication factors of disseminated intravascular coagulation, and implemented pharmaceutical monitoring during the course of drug treatment. Results After glucocorticoid treatment, the coagulation function of the patient improved. Conclusion Nivolumab may cause disseminated intravascular coagulation, which is rare in clinical practice, once similar symptoms occur, the diagnosis should be actively clarified, and timely treatment measures should be taken to ensure the safety of patients.